Skip Navigation


JAC Advance Access originally published online on October 8, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/5/735    most recent
dkf203v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pelak, B. A.
Right arrow Articles by Teppler, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pelak, B. A.
Right arrow Articles by Teppler, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 735-741
© 2002 The British Society for Antimicrobial Chemotherapy

Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection

Barbara A. Pelak1, Diane M. Citron2, Mary Motyl1, Ellie J. C. Goldstein2, Gail L. Woods3,* and Hedy Teppler3

1 Merck Research Laboratories, Rahway, NJ; 2 R. M. Alden Research Laboratory, Santa Monica, CA; 3 Merck Research Laboratories, BL 3-4, PO Box 4, West Point, PA 19846-0004, USA

Received 14 March 2002; returned 11 July 2002; revised 6 August 2002; accepted 12 August 2002

This study compared the in vitro activities of ertapenem, ceftriaxone, co-amoxiclav, ciprofloxacin and piperacillin–tazobactam against 314 aerobic bacteria and of ertapenem, piperacillin–tazobactam, cefoxitin, ceftriaxone, chloramphenicol, ticarcillin–clavulanate, ampicillin–sulbactam, clindamycin and metronidazole against 500 anaerobic bacteria from 212 patients with acute pelvic infection. Antimicrobial susceptibilities were determined by broth microdilution (aerobes) or agar dilution (anaerobes), following NCCLS guidelines. The most common isolates were Enterobacteriaceae and Peptostreptococcus spp. Ertapenem was the most active drug tested against Enterobacteriaceae (100% susceptible) and anaerobes (99.8% susceptible); the least active agents were co-amoxiclav (79% of Enterobacteriaceae susceptible) and ceftriaxone (85.9% of anaerobes susceptible). All agents tested had excellent activity against ß-haemolytic streptococci and methicillin-susceptible Staphylococcus aureus.

* Corresponding author. Tel: +1-484-344-2481; Fax: +1-484-344-3404; E-mail: gail_woods{at}merck.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. R. Noel, K. E. Bowker, and A. P. MacGowan
Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model
Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4234 - 4239.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Alhambra, J. A. Cuadros, J. Cacho, J. L. Gomez-Garces, and J. I. Alos
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics
J. Antimicrob. Chemother., June 1, 2004; 53(6): 1090 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. M. Livermore, A. M. Sefton, and G. M. Scott
Properties and potential of ertapenem
J. Antimicrob. Chemother., September 1, 2003; 52(3): 331 - 344.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.